Aptar has announced a new collaboration agreement with Chinese connected drug delivery specialist Sonmol for development of an inhaler monitoring system designed to “enable remote patient monitoring, improve patient and physician interactions, increase patient engagement and adherence, and improve health outcomes” in China and other Asian countries. According to the announcement, Aptar Pharma has also made a strategic investment in Sonmol; the amount was not disclosed.
In 2016, Aptar Pharma partnered with Propeller Health for development of a connected MDI, and in 2018, the two companies announced a broader partnership for connected respiratory delivery and management. Aptar also launched its eDose MDI dose counter in 2016, and its eLockout device is used in Takeda’s Instanyl fentanyl nasal spray. Sonmol currently offers connected devices and health data management systems for respiratory diseases in China.
Sonmol CEO Luffy Lv said, “Aptar Pharma has a well-established position worldwide in drug delivery technologies across the whole value chain. Collaborating with Aptar will help us expand and speed up clinical application and commercialization of Sonmol’s innovative products. I look forward to more in-depth and innovative exploration and collaboration between Aptar and Sonmol in the field of drug and disease digital management in China and worldwide.”
Aptar Asia President Xiangwei Gong said, “We look forward to furthering digital respiratory medicines, diagnostics and patient support services in China and other Asian markets.”
Gael Touya, President of Aptar Pharma, added, “This partnership with Sonmol continues to develop our strategy in digital health, building platforms for customers and their patients worldwide. We look forward to our future collaboration.”
Read the Aptar press release.
